Citadel Securities Expands Team in India After Jane Street Saga
The market-making giant has tapped Prajual Maheshwari to join Citadel Securities India Markets Pvt. in Gurugram from high-frequency trading firm Aakraya Research in Mumbai, one of the people said, asking not to be named discussing private information. The Miami-based company aims to recruit more traders and senior roles at its Indian operations, the people added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Palantir stock drops 20% in a week, amid over-valuation concerns
Shares in the artificial intelligence software maker Palantir slid more 6% on Wednesday morning. The company's stock price has dropped around 20% over the past week, eradicating the gains made after it reported strong quarterly earnings on August 4. The report revealed that Palantir's quarterly revenue grew nearly 50% — four times the level of 2020 — and surpassed $1 billion for the first time, surpassing Wall Street's estimates and taking the company's stock to all-time highs. Palantir has been the biggest winner of any company in the S&P 500 so far this year, its share price more than doubling. Despite announcing a dazzling second quarter, its shares began to slip within a day, now falling for the sixth consecutive day of trading. One explanation for this is the broader AI pullback among investors on Tuesday. Shares in chipmakers AMD, Nvidia, and Broadcom were all in the red, dragging the S&P 500 down 0.59%. Catalyzing investor jitters was a report by The Verge on Monday that OpenAI CEO Sam Altman believes AI is in a bubble. "When bubbles happen, smart people get overexcited about a kernel of truth,' Altman reportedly told a group of reporters last week. 'Are we in a phase where investors as a whole are overexcited about AI? My opinion is yes. Is AI the most important thing to happen in a very long time? My opinion is also yes,' he was quoted as saying. However, Palantir's woes cannot be attributed solely to the industry-wide retreat. Some industry onlookers believe the company could be over-valued. Palantir's shares trade at more than 600 times earnings and about 120 times annual sales, ratios far beyond those seen in past tech booms, according to The Economist in an article published following the company's earnings report. To make those numbers plausible, revenues would need to rise more than fivefold within five years—demanding growth of over 40% annually, the piece continues. Amplifying valuation concerns: Last Friday, Bloomberg reported that OpenAI is preparing to sell around $6 billion in Palantir stock, which would value the company at a staggering $500 billion. It prompted analysts at Citron Research to write in a Monday note that the level of revenue growth required to justify its price-to-sales ratio is unrealistic. They say this comes down the limits of what Palantir is selling: data analytics. "Palantir has built its reputation selling tools to mine these mountains of data, but the market is waking up: you can't just throw more servers and code at the problem forever. Now, Palantir faces a familiar squeeze," analysts wrote. "The days of selling 'data fairy dust' are fading; it's time for Palantir to prove it can deliver something new and tangible, not just bigger numbers," they continued. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
QuantumScape (QS) Tumbles as 5 Execs Unload Stake
We recently published . QuantumScape Corporation (NYSE:QS) is one of Tuesday's worst performers. QuantumScape extended its losing streak to a fourth straight day on Tuesday, dropping 10.11 percent to close at $7.91 apiece as investors reacted to an insider selling spree in the previous trading sessions. In separate regulatory filings earlier this week, QuantumScape Corporation (NYSE:QS) revealed that five top executives, including chief executive officer Siva Sivaram, disposed of a significant chunk of their shares in the company. Source: pixabay Last Monday alone, Sivaram unloaded 100,178 shares for a total of $904,607, while Chief Legal Officer Michael McCarthy sold 45,371 shares for a total of $409,700. Chief Financial Officer Kevin Hettrich disposed of 46,837 shares for a total of $422,938, while co-founder and Chief Technology Officer Tim Holme sold 47,727 shares for $430,974. Meanwhile, Chief Development Officer Singh Mohit made two selling transactions, unloading 47,727 shares for $430,974 on Monday, followed by 23,598 shares for $204,165 on Tuesday, August 19. No reason was divulged for the selling transactions, except that the officers may have cashed in on gains following QuantumScape Corporation's (NYSE:QS) climb to almost $10 level last week. While we acknowledge the potential of QS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Global Mass Spectrometry Market to Reach USD 9.62 Billion by 2030 Amid Rising Pharmaceutical R&D, Environmental Testing, and AI-Powered Advancements: MarkNtel Advisors
NEW DELHI, Aug. 20, 2025 /PRNewswire/ -- The Global Mass Spectrometry Market size valued at approximately USD 6.9 billion in 2024, is projected to reach USD 10.38 billion by 2030, growing at a CAGR of around 7.04% during the forecast period from 2025 to 2030, according to MarkNtel Advisors. This market growth is driven by heightened concerns for public and environmental health, leading to increased food testing and sample testing. The rapid expansion of the pharmaceutical industry and the integration of AI in mass spectrometers are also pivotal. Various governments are significantly investing in mass spectrometry infrastructure, while hospitals and labs upgrade their medical devices with advanced systems. However, challenges like high operational costs and a shortage of trained professionals persist, especially in remote areas. Overall, these factors create ample growth opportunities for stakeholders in the evolving landscape of analytical techniques, biotechnology innovation, and healthcare quality control. Mass Spectrometry Market Report Scope: Study Period: 2025-2030 Growth Rate (CAGR): 7.04% During 2025-30 Market Size (2024): USD 6.9 Billion Market Value (2030): USD 10.38 Billion Leading Region: North America Interested User Can Get a FREE sample of the report here: Top Mass Spectrometry Manufacturers/Companies Worldwide The Mass Spectrometry Global Market is seeing dynamic activity from top mass spectrometry manufacturers/companies aiming to expand their market share. Key players like Thermo Fisher Scientific Inc., Agilent Technologies Inc., and Waters Corporation are leading the way, alongside Danaher Corporation, Bruker Corporation, and Shimadzu Corporation. Companies such as PerkinElmer Inc., JEOL Ltd., LECO Corporation, and Advion Inc. are actively pursuing mergers, collaborations, and acquisitions to enhance their competitive advantage. Their focus on innovation, research and development, and diverse product portfolios positions them for sustained growth in an evolving industry. With a commitment to improving operational efficiency and addressing market demands, these firms are shaping the future of analytical instruments and driving revenue growth in the mass spectrometry sector. Rising Demand Across Key Sectors Mass spectrometry has become a cornerstone technology for high-precision analytical testing, enabling industries to identify, quantify, and characterize chemical compounds with unmatched accuracy. The surge in adoption is driven by multiple high-growth sectors: Pharmaceuticals & Biotechnology: Increased spending on drug discovery, diagnostics, and biomarker identification is fueling demand. LC-MS and hybrid spectrometers are now essential for nitrosamine impurity testing, compliance with FDA and EMA regulations, and advanced proteomics research. Environmental Testing: With growing concerns around PFAS, microplastics, and nitrosamines, mass spectrometry is emerging as the go-to tool for regulatory bodies such as the U.S. EPA, which has approved LC-MS/MS protocols (Methods 533 & 537.1) for drinking water testing. Food & Beverage Safety: Rising global emphasis on quality assurance (QA) protocols, contaminant detection, and chemical residue analysis is creating new demand for advanced MS solutions. Energy & Climate Research: Mass spectrometers are being deployed for climate modeling, energy exploration, and environmental monitoring, aligning with sustainable development goals. Market Dynamics: Key Drivers Emerging Contaminants Testing: The rapid evolution of contaminants like PFAS, nitrosamines, and microplastics has made mass spectrometry indispensable for compliance and research. Growing Pharma R&D Budgets: With double-digit YOY increases in pharmaceutical R&D spending, mass spectrometry is becoming central to both drug discovery and quality control (QC) processes. Government Regulations: Stringent drug safety protocols, environmental monitoring standards, and food safety laws are pushing adoption globally. Access Complete Data Tables, Forecasts, Segment, and Competitor Profiles Here: Growth Restraints High Cost of Systems: Instruments range from USD 75,000 to USD 500,000 depending on type and configuration, with GC-MS averaging USD 50,000–115,000 and single-mass systems priced at USD 350,000–400,000. Operational & Training Costs: In addition to capital investment, users face maintenance, calibration, reagent, and skilled labor costs. Smaller labs face difficulties due to infrastructure limitations. Skilled Workforce Shortage: Efficient MS usage requires specialized training in sample preparation, method development, and troubleshooting. With only four researchers per 10,000 workers in India and a projected 65,000 bio-economy professionals needed in Canada by 2029, the talent gap could slow adoption. Opportunities Technological Advancements: Breakthroughs in AI integration, machine learning, mass spectrometry imaging (MSI), high-resolution MS (HRMS), and miniaturized portable MS devices are broadening applications across healthcare, forensic science, and diagnostics. OMICS Revolution: Growth in proteomics, genomics, and metabolomics is creating opportunities in personalized medicine, diabetes research, and congenital disorder screening. Portable Solutions: Field-deployable MS systems now allow real-time on-site diagnostics in environmental testing, agriculture, and border security. Future Trends: The global mass spectrometry market is witnessing a significant trend with the integration of artificial intelligence in mass spectrometers. This innovation enhances the efficiency of these medical devices, allowing for faster and more accurate results compared to traditional methods that require manual analysis. Companies like Agilent, Thermo Fisher, Bruker, and Waters are leading the charge in manufacturing AI-enabled mass spectrometers. For example, Thermo Fisher Scientific launched the Orbital Astral Zoom MS in 2025, which utilizes AI software via the Ardia platform for improved multiplexing and scanning speeds. Agilent Technologies also introduced the InfinityLab Pro iQ series in 2025, featuring AI-powered compact Liquid Chromatography-Mass Spectrometry (LC-MS). This system autonomously detects faults and suggests corrections, showcasing how AI advancements are effectively transforming the mass spectrometry landscape. Global Mass Spectrometry Market Segmentation Analysis: By Product Type: Based on mass spectrometry product type segment market is led by instruments, particularly hybrid mass spectrometers. These devices combine different mass analyzers, enhancing sensitivity and accuracy. Their ability to generate complex data quickly drives widespread adoption and necessitates software for data management. By Application: The OMICS research segment is projected to grow notably in mass spectrometry. Its applications in diagnostics and biomarker identification, particularly in biopharma and genomics, are driving advancement, especially in diabetes and newborn screening. By End User: The pharmaceutical sector is expected to see the fastest growth in mass spectrometry. Increased regulations in drug manufacturing and advancements in QC processes are pushing pharmaceutical companies to adopt mass spectrometers, solidifying their dominant position in the market. Regional Insights: North America Leading Growth North America South America Europe The Middle East & Africa Asia-Pacific North America leads the mass spectrometry market, holding a 38% share, thanks to its robust pharmaceutical and biotech sectors. Key companies like Pfizer, Johnson & Johnson, and Merck in the U.S., along with Canada's Apotex, drive innovation in drug discovery and testing. Significant government and private funding for R&D, such as grants from the National Institutes of Health and the Canada Foundation for Innovation, further bolster the region's market position. These investments highlight North America's prominent role in advancing mass spectrometry technology. Request Your Custom Global Mass Spectrometry Market Report – Regional or Country Specific – Get tailored insights for your exact target market. Related Questions You May Find Helpful: Q1: How big is the global mass spectrometry market? The market was USD 6.33 billion in 2024 and is projected to reach USD 9.62 billion by 2030 at a 7.2% CAGR, driven by pharma R&D, food safety testing, and environmental monitoring. Q2: How expensive is a mass spectrometer? Costs range from USD 75,000 to USD 500,000. GC-MS averages USD 50,000–115,000, while advanced hybrid and high-resolution systems exceed USD 400,000. Q3: What are the latest advancements in mass spectrometry market? In 2025, Agilent Technologies Inc. introduced the InfinityLab Pro iQ Series, which includes the Pro iQ and Pro iQ Plus LC–MS detectors designed for quicker, smarter, and more automated laboratory processes. Alongside, they upgraded the 8850 GC system for compatibility with mass spectrometry. These innovations are smaller, faster, and more eco-friendly, earning certification from My Green Lab for sustainability. Q4: What are the future trends of mass spectrometry? Integration of artificial intelligence with MS devices is one of the key trends shaping the growth of the Mass Spectrometry Market. Q5: What are the downsides of mass spectrometry? Challenges include high upfront costs, ongoing consumable expenses, complex operation, infrastructure needs, and a global shortage of skilled analysts. Q6: What is the difference between MS, MS/MS, and LC-MS? MS identifies compounds by mass-to-charge ratio. MS/MS (tandem MS) provides deeper structural data using two analyzers. LC-MS couples liquid chromatography with MS for separating complex mixtures before analysis. Q7: How is mass spectrometry used in the pharmaceutical industry? Pharma companies rely on MS for drug discovery, nitrosamine impurity profiling, biologics QC, biomarker validation, and regulatory compliance testing. Q8: Do hospitals and clinical labs use mass spectrometry? Yes. Hospitals use MS for toxicology, newborn screening, infectious disease biomarker testing, therapeutic drug monitoring, and personalized medicine diagnostics. Q9: What is the difference between NMR and MS? NMR uses magnetic resonance to analyze molecular structure. MS determines mass-to-charge ratios for chemical identification and are complementary in drug development and biomolecular research. Q10: Who are the leaders and manufacturers in the mass spectrometry market? Key players include Agilent, Thermo Fisher, Danaher (SCIEX), Waters, Bruker, Shimadzu, PerkinElmer, JEOL, and Hitachi High-Tech. Q11: Why are spectrometers so expensive? They require precision engineering, high-tech detectors, proprietary software, costly consumables, and rigorous calibration standards, which increase price. Q12: What industries will drive future MS adoption? Growth will be strongest in pharma & biotech, food & beverage safety, environmental testing, clinical diagnostics, energy/petrochemicals, and forensic sciences. MarkNtel Blogs: Key Players Boosting Japan Anime Merchandising Industry Growth - Top AV Cable Companies Driving Residential Connectivity in South Korea - Top Companies in Japan Wax Industry - India Sports Nutrition Top Brands to Watch in 2025 - Top Companies Operating in Online Gaming Market - Key Brands in India Bath Soap Market - Top 10 Electric Vehicle Companies in India 2025: From Startups to Auto Giants- Top 7 ATM Companies Shaping the Global Market Landscape - Top Pan Masala Brands in India - About Us MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others. We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others. Logo: Contact Us:MarkNtel AdvisorsOffice No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, IndiaContact No: +91 8719999009Email: sales@ Visit our Website: Content Source: View original content: SOURCE MarkNtel Advisors
